出版社 | MarketsandMarkets |
出版年月 | 2025年1月 |
Next-generation Sequencing (NGS) Market – Global Forecast To 2029
The next-generation sequencing market is expected to reach USD 22.38 billion in 2029 from USD 13.28 billion in 2024, at a CAGR of 11.0% during the forecast period.
次世代シーケンス市場は、予測期間中のCAGR 11.0%で、2024年の132億8,000万米ドルから2029年には223億8,000万米ドルに達すると予想されています。
The increasing adoption of NGS in areas like oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is a major growth driver. Moreover, improved bioinformatics tools for data analysis and interpretation are enhancing the usability of NGS, driving its widespread adoption.
腫瘍学、感染症、リプロダクティブ・ヘルス、メタゲノミクス、個別化医療などの分野における NGS の採用の増加が、主要な成長原動力となっています。さらに、データ分析と解釈のための改良されたバイオインフォマティクス ツールにより NGS の使いやすさが向上し、NGS の普及が促進されています。

List of Companies Profiled in the Report:
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Danaher Corporation (US)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (US)
- Revvity (US)
- Eurofins Scientific (Luxembourg)
- PacBio (US)
- Oxford Nanopore Technologies plc. (UK)
- Takara Bio Inc. (Japan)
- BGI Group (China)
- Merck KGaA (Germany)
- BD (US)
- 10X Genomics (US)
- New England Biolabs (US)
- Promega Corporation (US)
- Novogene Co., Ltd. (China)
- LGC Limited (UK)
- WuXi Biologics (China)
- MGI Tech Co. Ltd. (China)
- Tecan Trading AG (Switzerland)
- Twist Biosciences (US)
- Azenta US, Inc. (US)
- GenScript (US)
- SD Biosensor, Inc. (South Korea)
- Fulgent Genetics (US)
- Hamilton Company (US)
- Zymo Research Corporation (US)
- NeoGenomics Laboratories (US)
- Psomagen (US)
The report provides insights on the following pointers:
Analysis of key drivers (Advancements in sequencing platforms, Rising clinical applications of sequencing, Growing demand for precision medicine, Declining sequencing cost), restraints (Data analysis complexity, High initial capital investment), opportunities (Integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (Standardization issues) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products/services of the NGS market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the genomics market
- Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US).